Drug
Tirbanibulin
Tirbanibulin: highest development phase Post-Market, developed by Almirall. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Almirall
Trials
| Drug | Phase | Indication |
|---|---|---|
| Tirbanibulin 2.5 mg ointment NCT05741294 | Post-Market | Actinic Keratosis |
| Tirbanibulin NCT06026358 | Post-Market | Actinic Keratoses |
| Tirbanibulin NCT06135415 | Phase 3 | Keratosis, Actinic |
Latest
No recent events.
Follow Tirbanibulin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.